Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride.

Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Abstract Text:

H F Fehr,

In a 28-day non-blinded study of 1071 patients with functional dyspeptic symptoms in a general practice setting, 666 presented with mainly typical symptoms of functional dyspepsia and received 5 mg cisapride three times daily, while 405 with predominating symptoms indicative of gastroesophageal reflux received 10 mg cisapride three times daily. On the basis of an anamnestic risk factor analysis for organic lesions, 'low-risk' patients were to be treated directly with cisapride, while for 'high-risk' patients a more thorough gastrointestinal examination was recommended before starting cisapride. Of patients in the dyspepsia group 75% reported a good or excellent response; the corresponding rate was 80% in the reflux group. Low-risk patients in both groups tended to respond better than high-risk patients (mean difference, 11%). Patients and investigators reached identical assessments of response. Concomitant antacids, calcium antagonists, beta-blockers and sedatives did not affect the results, but concomitant NSAIDs reduced the mean improvement rate by 14% (p < 0.01). Adverse effects such as abdominal cramps and loose stools were uncommon (< or = 3.4%).

Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Publishing Authors By Initials

HF Fehr,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Journal Published:

PUBLICATION TYPE: Multicenter Study

Journal: Scandinavian journal of gastroenterology. Suppleme

VOLUME: 195

Page Numbers: 40-5; discussion 45-6

Journal Abbreviation: Scand. J. Gastroenterol. Suppl

ISSN: 0085-5928

DAY: 13

MONTH: 02

YEAR: 1993

Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 437034

Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. Information

Substance Name: Cisapride

Registry Number: 81098-60-4

Grant and Affiliation Information for Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride.

AFFILIATION: Dept. of Gastroenterology, Kantonsspital, Aarau, Switzerland.

Country: NORWAY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Scand J Gastroenterol Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride Related Publications

• Catalytic enantioselective tautomerization of isolated enols.
• G-CSF-induced remission in two cases of acute myeloid leukemia.
• Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation.
• Not Available
• Recurrent bleeding after variceal hemorrhage: predictive value of portal venous duplex sonography.
• Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride.
• Studying the neurobiology of social interaction with transcranial direct current stimulation--the example of punishing unfairness.
• The neural signature of social norm compliance.
• The role of taurocholic acid, glycocholic acid and lysolecithin in experimental stress ulcer in the rat.
• [A different headache]
• [BREAST CANCER AND ITS TREATMENT.]
• [Catastrophic sequelae of incorrect immobilization of the fingers.]
• [Comparison of a D-dimer rapid-test with a plasma-immunoassay for diagnosis of venous thrombosis or pulmonary embolism in a medical emergency unit]
• [Effusion of the knee joint]
• [Extraperitoneal radical prostatectomy Da Vinci]
• [FAB classification of acute leukemias--10-year experience]
• [High-dose gamma globulin therapy in immune thrombopenia]
• [Interferon therapy of hairy cell leukemia and chronic myeloid leukemia]
• [Malignant hematologic diseases]
• [Mast cells and basophils and their disorders]
• [Minimal invasive surgery in gynaecology]
• [Myeloproliferative disorders]
• [On dislocations of the elbow joint]
• [On some drawings of a delirious schizophrenic]
• [Problems of appendicitis]
• [The clinical significance of CRP (C-reactive protein) monitoring]
• [Treatable disorientation?]
• [Value of the blood picture and flow cytometry immunotyping in the early diagnosis of low-grade lymphoma]
• [What can be expected of a Cancer Detection Center?]
• [When eating becomes painful. Herpes simplex virus type 1 esophagitis]